ReviewTransboundary and emerging diseases2025
The Potential of Disabled Infectious Single Cycle (DISC) Virus Platforms for Next Generation African Swine Fever Vaccine Development.
Review in Transboundary and emerging diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
African swine fever (ASF) is an emergency animal disease causing significant socio-economic impacts in affected areas on a global scale. While the first generation of ASF live-attenuated virus (LAV) vaccines to be recently approved for use in some countries offer potential to kerb the spread of ASF, non-live next-generation vaccines offer a safer alternative that can also be administered to animals in ASF-free zones. Among the next-generation vaccine platforms, disabled infectious single cycle (DISC) viruses are a promising replication-incompetent viral vaccine approach. In this review, we evaluate potential ASF virus gene targets that have been shown to have essential roles in the replication cycle and could be selected as deletion targets for producing DISC vaccines. We also summarise ASF virus genes for which there is evidence for a role in replication but have not yet been examined for their essential functions. Anticipated challenges for the development of an ASF DISC vaccine include limited cell substrates for development and manufacturing, genomic and phenotypic diversity of ASFV and potential for recombination events with co-infecting field viruses leading to reversion to virulence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.